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sparing.  
Materials and Methods: We retrospectively analyzed 10 adult 
patients undergoing CSI at our institution. All patients were 
treated with TomoTherapy (Accuray, Palo Alto, USA). For 
comparison, all treatment plans were standardized for 
delivery of 36 Gy. The plans were not specifically optimized 
for bone marrow sparing. Additionally, for each patient we 
calculated a 3D conventional plan (3D-CRT) using two 
opposed cranial fields with two attached spinal fields. Based 
on the published data by J.A.Hayman et al. active bone 
marrow compartments were delineated. We compared the 
treatment plans (TomoTherapy vs. 3D-CRT) with respect to 
the mean values for the whole active bone marrow and 
calculated 'weighted bone marrow exposure' (WBME). We 
defined WBME as the sum of all products of mean 
proliferating bone marrow according to anatomical site and 
the mean dose to the anatomical site based on the results of 
J.A. Hayman et al.: WBME =∑(mean marrow according to 
anatomical site * mean dose to anatomical site). 
Results: Mean of mean doses accross all patients for the 
particular bone marrow compartments are shown in the table 
1. Mean values for the whole active bone marrow were higher 
in TomoTherapy plans for each patient with the mean 
difference of ca. 19% (Range 13-37%). Also when taken into 
account the WBME, TomoTherapy treatment plans delivered 
higher dose to active bone marrow in each patient, however 
the mean difference was lower – ca. 13% (Range 2-25%). 
Table 1: Mean of mean doses according to the particular 
bone marrow compartment 
 
 
Conclusions: If not optimized to spare active bone marrow 
CSI, 3D-CRT is superior to TomoTherapy with respect to 
active bone marrow sparing. Except for the sternum, 3D-CRT 
results in almost equivalent or better dose sparing of all bone 
marrow compartments. To evaluate the bone marrow sparing 
the use of WBME seems prudent as the quantitative active 
bone marrow distribution doesn’t follow the absolute bone 
marrow distribution. Whether active bone marrow sparing 
optimized TomoTherapy plans yield superior results is a 
matter of ongoing research. 
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Purpose/Objective: Proper staging of intracranial disease 
with an accurate assessment of the exact number of brain 
lesions is of utmost importance in the decision-making 
process for the appropriate treatment of patients with brain 
metastases. The diagnostic efficacy in the detection of 
additional brain metastases of a three-dimensional, T1-
Weighted Gradient-Echo Imaging with a double contrast was 
evaluated 
Materials and Methods: Before undergoing radiosurgical 
treatment, patients underwent a brain magnetic resonance 
imaging (MRI) scan to be used during the treatment planning 
in order to contour the targets and to locate the brain lesions 
as they relate to the stereotactic frame.  
All the patients underwent a post-contrast study with T1-
weighted, 3D Magnetization-Prepared Rapid Acquisition 
Gradient Echo (MP RAGE) sequence. We used a double dose 
of gadobenate dimeglumine and slice thickness of 1 mm.  
Results: Starting from October 2012 to August 2014, we 
treated with Gamma Knife radiosurgery (GKRS) 113 patients 
with brain metastases. On the diagnostic MRI, all the patients 
had a number of lesions ≤4. Median time interval between 
diagnostic MRI scan and the day of GKRS was 13 days (range 
5-22)  
A total of 87 additional lesions were detected on MR imaging 
performed in the same day of the GKRS in forty patients out 
of 113 (35.4%). A median number of 2 additional lesions were 
detected (range 1-11). Among these 40 patients only 18 
patients had a number of lesions ≤4 on the day of treatment. 
Patients with a total number of lesions ≤10 were treated with 
GKRS. Two patients with a total number of lesions > 10 were 
treated with whole brain radiotherapy (WBRT).  
Conclusions: A double-contrast study with T1-weighted, 
volumetric MPRAGE sequence, using acquisition of contiguous 
1-mm slices may offer a definitely better staging for patients 
with brain metastases. In our opinion, a diagnostic high 
resolution MRI should be recommended in all the patients 
with newly diagnosed brain metastases because the detection 
of the real number of lesions is crucial for an adequate 
treatment and it also may lead to choose different 
therapeutic strategies other than radiosurgery.  
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Purpose/Objective: CNAO (Centro Nazionale di Adroterapia 
Oncologica) started clinical activity with proton beam in 
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September 2011, and with Carbon ion beam in 2012. 
Skullbase chordomas are known as radioresistant tumors. 
Escalating the dose to target volumes and sparing normal 
organs is recommended to ensure adequate local control with 
low toxicity.  
Materials and Methods: Since September 2011, 67 patients ( 
F/M : 25/42) with histologically verified diagnosis of skullbase 
chordomas have been treated at CNAO. All patients 
underwent first one or more surgical procedures, and then 
were irradiated on macroscopic residual disease or on the 
site of local relapse ( 2 patients had local relapse after 
complete resection). Thirty nine patients have been treated 
with proton beam, up to a total dose of 74 GyE in 37 
fractions, 2 GyE/fraction over 5 days per week, twenty eight 
patients with carbon ion up to70.4 GyE in 16 fractions, 4.4 
GyE/fraction over 4 days per week. Each patient underwent 
clinical examination during, at the end and every three 
months after the treatment. Acute and late toxicity data 
were recorded according to CTCAE v.4.0 score. Clinical 
outcome was evaluated with trimestral MRI according to 
RECIST criteria. 
Results: Treatment has been in general well tolerated, with 
acute toxicity G0/G1, G2 and G3 reported respectively in 
74%, 24% and 2% patients; one patient died for causes not 
treatment related. 
With 15 months median follow up time ( range 2 – 27), local 
control was achieved in 51 patients (over the 54 who reached 
the first follow up visit), partial response in 2, and complete 
response in 1. No progression disease has been reported. In 
the 34 patients who reached 12 months follow up, 26 patients 
were scored with late toxicity G0/G1 (alopecia, fatigue, 
dysphagia, headache, hearing loss), and 8 patients with G2 
(pituitary deficit, neuropathy, asymptomatic brain 
dysfuncion). 
Conclusions: Our data show safety and effectiveness of 
handrontherapy for skullbase chordomas although the limited 
number of patients and the short follow up time. Longer 
follow up are needed. 
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Purpose/Objective: In brain 1H Magnetic Resonance 
Spectroscopic Imaging (MRSI) elevated choline and reduced 
NAcetylAspartate (NAA) levels are both indicators of 
cancerous tissue and the Choline/NAA Ratio (CNR) is a widely 
studied parameter for evaluating tumor metabolic function. 
In this study we compare CNRs in healthy tissue and tumor 
across a cohort of GlioBlastoma Multiforme (GBM) patients 
and investigate the link between spectroscopic abnormality 
and disease-free survival after treatment. 
Materials and Methods: 14 patients diagnosed with GBM 
underwent an MRSI exam as part of the (post-operative) 
radiotherapy treatment planning imaging process. The scan 
was a PRESS localized CSI with 10x10x8 voxels of 
approximately 0.5cc, TE/TR=135ms/1.5s. Data was 
processed, quantified, registered to the coacquired T1 
contrast enhanced scan and resampled to the T1 resolution 
using a custom tool developed in-house. After treatment, 
every patient received follow up MRIs every 1-2 months until 
relapse. 
Amongst GBM patients a GTV to CTV margin of 20mm is 
typically used to account for microscopic spread. Voxels 
greater than 20mm outside the CTV contour were classified 
as 'normal' and for each patient a Gaussian distribution was 
fitted to the CNRs of these voxels to obtain a mean normal 
CNR. As the CNRs in the contrast enhanced region do not 
typically form a Gaussian distribution, the median value was 
utilised. The Choline/NAA Enhancement (CNE) was defined as 
the ratio between median tumour CNR and mean normal 
CNR. 
Results: The normal tissue CNR across the group was 0.84 +/- 
0.10, showing a wide range of healthy tissue values across 
patients. Four patients exhibited no voxels with 
spectroscopic abnormalities. The mean CNE was 1.73 +/- 
0.65. 
Patients were divided into two groups (equal in number) 
based on the mean CNE and disease-free survival curves for 
both were constructed using the Kaplan-Meier estimator, 
shown in the figure, then compared using the log rank test, 
which showed a significant difference (p=0.00645) between 
the two groups.  
 
 
Conclusions: Our study found the baseline levels of 
metabolites to vary substantially between patients 
(attributable at least in part to tumor location), so that an 
absolute threshold for abnormal CNR cannot be determined 
for all patients. Instead we proposed a measure of relative 
abnormality, CNE, which can be compared across patients. 
There is a statistically significant relationship between our 
CNE and the disease-free survival of our patient cohort. Thus 
this study demonstrates that spectroscopic analysis of the 
CNE could help guide treatment planning by indicating 
patients who might benefit from more radical radiotherapy 
options such as dose boosting. The metric could also be used 
to tailor patient follow-up in order to more closely monitor 
patients with high risk of early relapse. 
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